A PHASE 1, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 24 Oct 2022 Status changed from active, no longer recruiting to completed.
- 17 Oct 2022 Planned End Date changed from 3 Oct 2022 to 7 Oct 2022.
- 27 Sep 2022 Planned End Date changed from 14 Oct 2022 to 3 Oct 2022.